文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

立体定向放射外科治疗脑转移瘤术后手术腔:单中心经验

Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience.
PubMed 文献 · Radiat Oncol · 2022-09-26

本研究评估脑转移瘤手术切除后对瘤床行术后伽玛刀立体定向放射外科的疗效与耐受性。2011年2月至2016年12月,本中心对64例患者、65个手术腔行伽玛刀治疗,中位随访11.1个月,1年局部无复发率97.5%、颅内无复发率57.6%、总生存率62.4%,仅1例组织学证实放射性坏死。作者认为该技术有效且耐受良好。

要点

  • 脑转移瘤切除后瘤床伽玛刀治疗,中位剂量20 Gy处方至50%等剂量线,中位治疗体积5.6 cc。
  • 1年局部无复发率97.5%,颅内无复发率57.6%,总生存率62.4%。
  • 多因素分析中非肺原发肿瘤与颅内无转移生存期下降显著相关(HR=8.04)。

核心结论

  • 作者认为脑转移瘤切除后术后伽玛刀是有效且耐受良好的技术,可治疗各种大小的体积(0.8至40 cc)。
  • 出现颅内复发时可进行重复立体定向放射外科或挽救性全脑放疗,从而推迟全脑放疗及其潜在副作用。

研究设计与样本

  • 单中心研究,2011年2月至2016年12月纳入64例患者、65个手术腔,均在肉眼完全手术切除后接受伽玛刀治疗。
  • 辅助放射外科的指征由多学科讨论决定,主要评估指标为局部控制、颅内无转移生存期、总生存期和毒性。

主要发现

  • 中位随访11.1个月,手术至放射外科中位时间35天,中位剂量20 Gy处方至50%等剂量线,中位治疗体积5.6 cc。
  • 4例患者(7%)出现局部复发;1年局部无复发率、颅内无复发率和总生存率分别为97.5%、57.6%和62.4%。
  • 共23例患者(41%)出现瘤床外颅内复发;1例组织学证实放射性坏死。
  • 单因素分析中,同时伽玛刀治疗多个病灶和瘤床与颅内无转移生存期下降相关(HR=1.16 [1.005-1.34] p=0.04)。
  • 多因素分析中,非肺原发肿瘤与颅内无转移生存期下降显著相关(HR=8.04 [1.82-35.4] p=0.006);体能状态评分升高和初始脑转移数目增多显著降低总生存期(HR=5.4 [1.11-26.3] p=0.037,HR=2.7 [1.004-7.36] p=0.049)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard therapy for brain metastasis was surgery combined with whole brain radiotherapy (WBRT). The latter is however, associated with important neurocognitive toxicity. To reduce this toxicity, postoperative stereotactic radiosurgery (SRS) is a promising technique. We assessed the efficacy and the tolerance to postoperative Gamma Knife radiosurgery (GK) on the tumor bed after resection of brain metastases. METHODS: Between February 2011 and December 2016, following macroscopic complete surgical resection, 64 patients and 65 surgical cavities were treated by GK in our institution. The indication for adjuvant radiosurgery was a multidisciplinary decision. The main assessment criteria considered in this study were local control, intracranial metastasis-free survival (ICMFS), overall survival and toxicity. RESULTS: Median follow-up: 11.1 months. Median time between surgery and radiosurgery: 35 days. Median dose was 20 Gy prescribed to the 50% isodose line, for a median treated volume of 5.6 cc. Four patients (7%) suffered from local recurrence. Local recurrence-free, intracranial recurrence-free and overall survival at 1 year were 97.5%, 57.6% and 62.4% respectively. In total, 23 patients (41%) suffered from intracranial recurrence outside the tumor bed. In univariate analysis: concomitant GK treatment of multiple lesions and the tumor bed was associated with a decrease in ICMFS (HR = 1.16 [1.005-1.34] p = 0.04). In multivariate analysis: a non-lung primary tumor was significantly associated with a decrease in ICMFS (HR = 8.04 [1.82-35.4] p = 0.006). An increase in performance status (PS) and in the initial number of cerebral metastases significantly reduced overall survival (HR = 5.4 [1.11-26.3] p = 0.037, HR = 2.7 [1.004-7.36] p = 0.049, respectively) and One radiation necrosis histologically proven. CONCLUSION: Our study confirmed that postoperative GK after resection of cerebral metastases is an efficient and well-tolerated technique, to treat volumes of all sizes (0.8 to 40 cc). Iterative SRS or salvage WBRT can be performed in cases of intracranial relapse, postponing WBRT with its potential side effects.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cantaloube M, Boucekine M, Balossier A, et al. Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience. Radiat Oncol. 2022. PMID: 36163026. doi:10.1186/s13014-022-02118-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。